What payers will ask
Is the clinical benefit the kind payers reward? — Clinical effectiveness
Enzalutamide plus ADT shows moderate benefit over ADT alone, with trial results indicating an increase in progression-free survival. However, overall survival data is still immature, leading to some uncertainty in the magnitude of the benefit.
Does the economic case hold at the expected price? — Cost effectiveness
The cost-effectiveness estimates for enzalutamide plus ADT fall within the acceptable range for Healthcare resources, suggesting it is a cost-effective option for treating hormone-sensitive metastatic prostate cancer.
Is there quality-of-life evidence payers weigh? — Quality of life
The trials reported health-related quality of life as a secondary endpoint, indicating positive but moderate improvements. The evidence suggests that enzalutamide plus ADT is generally better tolerated than docetaxel plus ADT, which supports its use.
Does the safety profile hold up for payers? — Safety and Adverse Effects
Enzalutamide plus ADT has a very good safety profile, with mostly mild or moderate adverse events reported. The treatment is generally well tolerated compared to docetaxel plus ADT.
Was the drug compared against what payers expect? — Comparator Selection
The clinical trials compared enzalutamide plus ADT against appropriate comparators, including ADT alone and docetaxel plus ADT, which are relevant to current Healthcare practice.
Is the population defined the way payers need it? — Patient Population and Subgroups
The patient populations in the ARCHES and ENZAMET trials are broadly generalizable to Healthcare clinical practice, although some concerns about representativeness exist due to exclusions in the trials.
Does the drug fit how care is delivered and paid for? — Care Pathway Integration
Enzalutamide plus ADT can be integrated into existing treatment pathways with minor adjustments, as it is an oral treatment that requires less monitoring than intravenous options.
Are the wider system costs understood? — Resource Use and Cost Implications
The resource implications of enzalutamide plus ADT are manageable, and the treatment is expected to provide a good balance of cost and benefit, aligning with Healthcare planning.
Would the evidence survive payer scrutiny? — Evidence Quality and Robustness
The evidence base is supported by two robust RCTs (ARCHES and ENZAMET), although some methodological concerns and uncertainties regarding overall survival persist.
How exposed is the case to uncertainty? — Uncertainty, Sensitivity, and Broader Impacts
While there is some uncertainty regarding long-term outcomes and the comparative effectiveness of enzalutamide plus ADT versus docetaxel plus ADT, the context of unmet need and patient preference supports its use.
